检索结果-南通市图书馆

Effect and Safety of Herbal Medicine Foot Baths in Patients with Diabetic Peripheral Neuropathy:A Multicenter Double-Blind Randomized Controlled Trial

在线全文

学校读者我要写书评

暂无评论

Chinese Journal of Integrative Medicine 2024年第3期30卷 195-202页

作者： HUANG Hao-yue LIN Yu-ping wei Hua FU Yu zhou Yue-hong FANG Zhao-hui QIU xiao-tang WANG Mei LI Qing-bo LI Shan-shan WANG Shi-dong DAI Fang LIU Zhen-jie ZHAO Ling WEN Jian-xuan wu Li-yan ZENG Hui-yan zhang jin-ming LU Qi-yun HE Liu SONG wei SUN Lu LUO Lu-lu HE Jia-li XIE Wen-wen LIANG Qing-shun HUANG Yuan ZHU Sheng-ling LONG Jie-er GAO Zhi-juan WEN Ze-huai LI chun-ji OUyanG Wen-wei LI Geng wu ming-hui LI An-xiang HUANG jin-zhu Sanjoy K Paul TANG Xian-yu FAN Guan-jie Department of Endocrinology Guangdong Provincial Hospital of Chinese MedicineGuangzhou510120China The Second Clinical College of Guangzhou University of Chinese Medicine Guangzhou510120China Department of Endocrinology The Second Affiliated Hospital of Guangzhou University of Chinese MedicineGuangzhou510120China Guangdong Provincial Academy of Chinese Medical Sciences Guangzhou510120China Department of Endocrinology The First Affiliated Hospital of Henan University of Chinese MedicineZhengzhou450000China Department of Endocrinology Liuyang Hospital of Chinese MedicineChangsha410000China Department of Endocrinology The First Affiliated Hospital of Anhui University of Chinese MedicineHefei230000China Department of Endocrinology Hainan Provincial Hospital of Traditional Chinese MedicineHaikou570100China Department of Endocrinology The Affiliated Hospital of Liaoning University of Traditional Chinese MedicineShenyang110000China Department of Geriatric Luoyang No.1 Hospital of Traditional Chinese MedicineLuoyangHenan Province471000China Department of Endocrinology The Second Affiliated Hospital of Guizhou University of Traditional Chinese MedicineGuiyang550000China Department of Endocrinology Beijing University of Chinese Medicine Affiliated Dongzhimen HospitalBeijing100000China Department of Endocrinology The First Affiliated Hospital of Guizhou University of Traditional Chinese MedicineGuiyang550000China Melbourne EpiCentre The University of Melbourne and Melbourne HealthMelbourne3013Australia

Objective:To evaluate the effect and safety of foot baths with Tangbi Waixi Decoction(TW)in treating patients with diabetic peripheral neuropathy(DPN).Methods:It is a multicenter double-blinded randomized controlled *** with DPN were recruited between November 18,2016 and May 30,2018 from 8 hospitals in *** patients received basic treatments for glycemic *** received foot baths with TW herbal granules either 66.9 g(intervention group)or 6.69 g(control group)for 30 min once a day for 2 weeks and followed by a 2-week rest,as a therapeutic *** the Toronto Clinical Scoring System total score(TCSS-TS)6 points,the patients received a total of 3 therapeutic courses(for 12 weeks)and were followed up for 12 *** primary outcome was change in TCSS-TS score at 12 and 24 *** outcomes included changes in bilateral motor nerve conduction velocity(MNCV)and sensory nerve conduction velocity(SNCV)of the median and common peroneal *** was also ***:Totally 632 patients were enrolled,and 317 and 315 were randomized to the intervention and control groups,*** the 12-week intervention,patients in both groups showed significant declines in TCSSTS scores,and significant increases in MNCV and SNCV of the median and common peroneal nerves compared with pre-treatment(P0.05),and no serious adverse event was related with ***:Treatment of TW foot baths was safe and significantly benefitted patients with DPN.A low dose of TW appeared to be more effective than a high dose.(Registry *** CTR-IOR-16009331)

关键词： diabetic peripheral neuropathy herbal medicine foot baths Chinese medicine randomized controlled trial Tangbi Waixi Decoction

Incidence and prognosis of olfactory and gustatory dysfunctions related to SARS-CoV-2 Omicron strain infection in China:A national multicenter survey of 35,566 individuals

在线全文

学校读者我要写书评

暂无评论

World Journal of Otorhinolaryngology-Head and Neck Surgery 2024年第2期10卷 113-120页

作者： Meng-Fan Liu Rui-Xia Ma Xian-Bao Cao Hua zhang Shui-hong zhou wei-hong Jiang yan Jiang jing-wu Sun Qin-Tai yang Xue-Zhong Li Ya-Nan Sun Li Shi Min Wang Xi-Cheng Song Fu-Quan Chen xiao-Shu zhang hong-Quan wei Shao-Qing Yu Dong-Dong Zhu Luo Ba Zhi-wei Cao Xu-Ping xiao Xin wei Zhi-hong Lin Feng-hong Chen chun-Guang Shan Guang-Ke Wang jing Ye Shen-hong Qu Chang-Qing Zhao Zhen-Lin Wang Hua-Bin Li Feng Liu xiao-Bo Cui Sheng-Nan Ye Zheng Liu Yu Xu xiao Cai wei Huang Ru-Xin zhang Yu-Lin Zhao Guo-Dong Yu Guang-Gang Shi Mei-Ping Lu yang Shen Yu-Tong Zhao Jia-hong pei Shao-Bing Xie Long-Gang Yu Ye-Hai Liu Shao-wei Gu Yu-Cheng yang Lei Cheng Jian-Feng liu Graduate School of Beijing University of Chinese Medicine BeijingChina Department of Otorhinolaryngology Head and Neck Surgery China-Japan Friendship HospitalBeijingChina Department of Otorhinolaryngology Head and Neck Surgery The First People's Hospital of YinchuanYinchuanChina Department of Otorhinolaryngology The First People's Hospital of Yunnan ProvinceKunmingChina Department of Otorhinolaryngology The First Affiliated Hospital of Xinjiang Medical UniversityUrumqiChina Department of Otorhinolaryngology Head and Neck Surgery The First Affiliated Hospital of Zhejiang University School of MedicineHangzhouChina Department of Otorhinolaryngology Head and Neck Surgery Xiangya Hospital Central South UniversityChangshaChina Department of Otorhinolaryngology Head and Neck Surgery The Affiliated Hospital of Qingdao UniversityQingdaoChina Department of Otorhinolaryngology Head and Neck Surgery The First Affiliated Hospital of USTCHefeiChina Department of Otorhinolaryngology Head and Neck Surgery The Third Affiliated Hospital of Sun Yat-sen UniversityGuangzhouChina Department of Otorhinolaryngology Head and Neck Surgery Qilu Hospital of Shandong UniversityJinanChina Department of Otorhinolaryngology Head and Neck Surgery The Second Affiliated Hospital of Harbin Medical UniversityHarbinChina Department of Otolaryngology The Second Hospital of Shandong UniversityShandong UniversityJinanChina Department of Otorhinolaryngology Head and Neck Surgery Peking University People's HospitalBeijingChina Department of Otorhinolaryngology Head and Neck Surgery Yantai Yuhuangding HospitalQingdao UniversityYantaiChina Department of Otorhinolaryngology Head and Neck Surgery Xijing HospitalThe Fourth Military Medical UniversityXi'anChina Gansu Provincial Center for Disease Control and Prevention LanzhouChina Department of Otorhinolaryngology Head and Neck Surgery The First Affiliated Hospital of China Medical UniversityShenyangChina Department of Otorhinolaryngology Head and Neck Surgery Tongji Hospit

Objective:This cross-sectional study aimed to determine the epidemiology of olfactory and gustatory dysfunctions related to COVID-19 in ***:This study was conducted by 45 tertiary Grade-A hospitals in *** and offline questionnaire data were obtained from patients infected with COVID-19 between December 28,2022,and February 21,*** collected information included basic demographics,medical history,smoking and drinking history,vaccination history,changes in olfactory and gustatory functions before and after infection,and other postinfection symptoms,as well as the duration and improvement status of olfactory and gustatory ***:Complete questionnaires were obtained from 35,566 *** overall incidence of olfactory and taste dysfunction was 67.75%.Being female or being a cigarette smoker increased the likelihood of developing olfactory and taste *** received four doses of the vaccine or having good oral health or being a alcohol drinker decreased the risk of such *** infection,the average olfactory and taste VAS scores were 8.41 and 8.51,respectively;after infection,they decreased to 3.69 and 4.29 and recovered to 5.83 and 6.55 by the time of the *** median duration of dysosmia and dysgeusia was 15 and 12 days,respectively,with 0.5%of patients having symptoms lasting for more than 28 *** overall self-reported improvement rate was 59.16%.Recovery was higher in males,never smokers,those who received two or three vaccine doses,and those that had never experienced dental health issues,or chronic accompanying ***:The incidence of dysosmia and dysgeusia following infection with the SARS-CoV-2 virus is high in *** and prognosis are influenced by several factors,including sex,SARS-CoV-2 vaccination,history of head-facial trauma,nasal and oral health status,smoking and drinking history,and the persistence of accompanying symptoms.

关键词： epidemiologic studies incidence olfactory disorders prognosis SARS-CoV-2 taste disorders

CEPC Technical Design Report

在线全文

学校读者我要写书评

暂无评论

Radiation Detection Technology and Methods 2024年第1期8卷 I0003-I0016,1-1091页

作者： Waleed Abdallah Tiago Carlos Adorno de Freitas Konstantin Afanaciev Shakeel Ahmad Ijaz Ahmed xiaocong Ai Abid Aleem Wolfgang Altmannshofer Fabio Alves weiming An Rui An Daniele Paolo Anderle Stefan Antusch Yasuo Arai Andrej Arbuzov Abdesslam Arhrib Mustafa Ashry Sha Bai Yu Bai yang Bai Vipul Bairathi Csaba Balazs Philip Bambade Yong Ban Tripamo Bandyopadhyay Shou-Shan Bao Desmond P.Barber Ayse Bat Varvara Batozskaya Subash Chandra Behera Alexander Belyaev Michele Bertucci xiao-Jun Bi Yuanjie Bi Tianjian Bian Fabrizio Bianchi Thomas Biekotter Michela Biglietti Shalva Bilanishvili Deng Binglin Denis Bodrov Anton Bogomyagkov Serge Bondarenko Stewart Boogert Maarten Boonekamp Marcello Borri Angelo Bosotti Vincent Boudry Mohammed Boukidi Igor Boyko Ivanka Bozovic Giuseppe Bozzi Jean-Claude Brient Anastasiia Budzinskaya Masroor Bukhari Vladimir Bytev Giacomo Cacciapaglia Hua Cai Wenyong Cai wujun Cai Yijian Cai Yizhou Cai Yuchen Cai Haiying Cai Huacheng Cai Lorenzo Calibbi Junsong Cang Guofu Cao Jianshe Cao Antoine Chance Xuejun Chang Yue Chang Zhe Chang Xinyuan Chang wei Chao Auttakit Chatrabhuti Yimin Che Yuzhi Che Bin Chen Danping Chen Fuqing Chen Fusan Chen Gang Chen Guoming Chen Hua-Xing Chen Huirun Chen jinhui Chen Ji-Yuan Chen Kai Chen Mali Chen mingjun Chen mingshui Chen Ning Chen Shanhong Chen Shanzhen Chen Shao-Long Chen Shaomin Chen Shiqiang Chen Tianlu Chen wei Chen Xiang Chen xiaoyu Chen Xin Chen Xun Chen Xurong Chen Ye Chen Ying Chen Yukai Chen Zelin Chen Zilin Chen Gang Chen Boping Chen chunhui Chen Hok Chuen Cheng Huajie Cheng Shan Cheng Tongguang Cheng Yunlong Chi Pietro Chimenti Wen Han Chiu Guk Cho ming-chung Chu xiaotong Chu Ziliang Chu Guglielmo Coloretti Andreas Crivellin Hanhua Cui xiaohao Cui Zhaoyuan Cui Brunella D'Anzi Ling-Yun Dai Xinchen Dai Xuwen Dai Antonio De Maria Nicola De Filippis Christophe De La Taille Francesca De Mori Chiara De Sio Elisa Del Core Shuangxue Deng wei-Tian Deng Zhi Deng Ziyan Deng Bhupal Dev Tang Dewen Biagio Di Micco Ran Ding Siqin Dingl Yadong Ding Haiyi Dong Jianin AGH University of Science and Technology Faculty of Physics and Applied Computer ScienceKrakow Anhui University HefeiAnhui Applied Physics Department Federal Urdu University of ArtsScience and TechnologyIslamabad Banaras Hindu University Institute of ScienceVaranasi Bandirma Onyedi Eylul University Bandirma Beihang University Beijing Beijing Computational Science Research Center Beijing Beijing Conveyi LTD Beijing Beijing Glass Research Institute Co. LtdBeijing Beijing Institute of Technology Beijing Beijing Normal University Beijing Brown University ProvidenceRI Budker Institute of Nuclear Physics Novosibirsk Cadi Ayyad University Laboratory of Fundamental and Applied PhysicsPolydisciplinary FacultyMarrakech Cairo University Giza Center for Theory and Computation National Tsing Hua UniversityHsinchu Central China Normal University WuhanHubei Central South University ChangshaHunan Centro de Fisica Teorica de Particulas Universidade Tecnica de LisboaLisboa Chengdu KaitengSifang Digital Radio&TV Equipment Co. LtdChengduSichuan China academy of engineering physics MianyangSichuan China building materials academy Beijing China Center of Advanced Science and Technology Beijing China Institute of Atomic Energy Beijing China Jiliang University HangzhouZhejiang China Nuclear Instrument CO. LTDBeijing China University of Geosciences Beijing China University of Geosciences WuhanHubei China University of Mining and Technology XuzhouJiangsu China West Normal University NanchongSichuan Chongqing University Department of PhysicsChongqing Chulalongkorn University Bangkok City University of hong Kong Department of PhysicsHong Kong Cockcroft Institute Daresbury Cornell University IthacaNY CPPM(AMU/IPhU&CNRS/INP) Marseille Dalian Minzu University DalianLiaoning Dalian University of Technology Department of PhysicsDalian Deutsches Elektronen-Synchrotron DESY Hamburg Dzhelepov Laboratory of Nuclear Problems of Joint Institute for Nuclear Research(DLNP jinR) Dubna East China University Of Science And Technol

The Circular Electron Positron Collider(CEPC)is a large scientific project initiated and hosted by China,fostered through extensive collaboration with international *** complex comprises four accelerators:a 30 GeV Linac,a 1.1 GeV Damping Ring,a Booster capable of achieving energies up to 180 GeV,and a Collider operating at varying energy modes(Z,W,H,and tt).The Linac and Damping Ring are situated on the surface,while the subterranean Booster and Collider are housed in a 100 km circumference underground tunnel,strategically accommodating future expansion with provisions for a potential Super Proton Proton Collider(SPPC).The CEPC primarily serves as a Higgs *** its baseline design with synchrotron radiation(SR)power of 30 MW per beam,it can achieve a luminosity of 5×10^(34)cm^(-2)s^(-1)per interaction point(IP),resulting in an integrated luminosity of 13 ab^(-1)for two IPs over a decade,producing 2.6 million Higgs *** the SR power to 50 MW per beam expands the CEPC's capability to generate 4.3 million Higgs bosons,facilitating precise measurements of Higgs coupling at sub-percent levels,exceeding the precision expected from the HL-LHC by an order of *** Technical Design Report(TDR)follows the Preliminary Conceptual Design Report(Pre-CDR,2015)and the Conceptual Design Report(CDR,2018),comprehensively detailing the machine's layout,performance metrics,physical design and analysis,technical systems design,R&D and prototyping efforts,and associated civil engineering ***,it includes a cost estimate and a preliminary construction timeline,establishing a framework for forthcoming engineering design phase and site selection *** is anticipated to begin around 2027-2028,pending government approval,with an estimated duration of 8 *** commencement of experiments and data collection could potentially be initiated in the mid-2030s.

关键词： initiated exceeding precise

Bendamustine treatment of Chinese patients with relapsed indolent non-Hodgkin lymphoma: a multicenter, open-label, single-arm, phase 3 study

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Chinese Medical Journal 2021年第11期134卷 1299-1309页

作者： Yuan-Kai Shi xiao-Nan hong Jian-Liang yang wei Xu Hui-Qiang Huang Xiu-Bin xiao Jun Zhu Dao-Bin zhou xiao-hong Han Jian-Qiu wu ming-Zhi zhang Jie jin xiao-yan Ke wei Li De-pei wu Shen-Miao yang Xin Du Yong-Qian Jia Ai-chun Liu Dai-hong Liu Zhi-Xiang Shen Lian-Sheng zhang Leonard James Edward Hellriegel Department of Medical Oncology National Cancer Center/National Clinical Research Center for Cancer/Cancer HospitalChinese Academy of Medical Sciences&Peking Union Medical CollegeBeijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted DrugsBeijing 100021China Department of Medical Oncology Fudan University Shanghai Cancer CenterShanghai 200030China Department of Hematology The First Affiliated Hospital of Nanjing Medical UniversityNanjingJiangsu 210029China Department of Medical Oncology Sun Yat-sen University Cancer CenterGuangzhouGuangdong 510060China Department of Medical Oncology 307 Hospital of Chinese People’s Liberation ArmyBeijing 100071China Department of Lymphoma Peking University Cancer Hospital&InstituteBeijing 100142China Department of Hematology Peking Union Medical College HospitalChinese Academy of Medical Sciences&Peking Union Medical CollegeBeijing 100730China Department of Oncology Jiangsu Cancer Hospital&Jiangsu Institute of CancerNanjingJiangsu 210009China Department of Oncology The First Affiliated Hospital of Zhengzhou UniversityZhengzhouHenan 450052China Department of Hematology The First Affiliated Hospital of Zhejiang University College of MedicineHangzhouZhejiang 310003China Department of Hematology Peking University Third HospitalBeijing 100191China Department of Oncology Jilin University First Affiliated HospitalChangchunJilin 130021China Department of Hematology Jiangsu Institute of HematologyThe First Affiliated Hospital of Soochow UniversitySuzhouJiangsu 215006China Department of Hematology Peking University Institute of HematologyPeking University People’s HospitalBeijing 100044China Department of Hematology Guangdong General HospitalGuangzhouGuangdong 510062China Department of Hematology and Research Laboratory of Hematology West China Hospital of Sichuan UniversityChengduSichuan 610041China Department of Medical Oncology Harbin Medical University Cancer HospitalHarbinHeilongjiang 150001China Department of Hematolo

Background:Bendamustine was approved in China on May 26th,2019 by the National Medical Product Administration for the treatment of indolent B-cell non-Hodgkin lymphoma(NHL).The current study was the registration trial and the first reported evaluation of the efficacy,safety,and pharmacokinetics of bendamustine in Chinese adult patients with indolent B-cell NHL following relapse after chemotherapy and rituximab ***:This was a prospective,multicenter,open-label,single-arm,phase 3 study(NCT01596621;C18083/3076)with a 2-year follow-up *** patients received bendamustine hydrochloride 120 mg/m2 infused intravenously on days 1 and 2 of each 21-day treatment cycle for at least six planned cycles(and up to eight cycles).The primary endpoint was the overall response rate(ORR);and secondary endpoints were duration of response(DoR),progression-free survival(PFS),safety,and *** were classified according to their best overall response after initiation of *** of patients in each response category(complete response[CR],partial response[PR],stable disease,or progressive disease)were summarized along with a twosided binomial exact 95%confidence intervals(CIs)for the ***:A total of 102 patients were enrolled from 20 centers between August 6th,2012,and June 18th,*** the time of the primary analysis,the ORR was 73%(95%CI:63%–81%)per Independent Review Committee(IRC)including 19%CR and 54%*** the follow-up period,the median DoR was 16.2 months by IRC and 13.4 months by investigator assessment;the median PFS was 18.6 months and 15.3 months,*** most common non-hematologic adverse events(AEs)were gastrointestinal toxicity,pyrexia,and *** 3/4 neutropenia was reported in 76%of *** AEs were reported in 29 patients and five patients died during the *** analysis indicated that the characteristics of bendamustine and its metabolites M3 and M4 were generally consistent

关键词： Bendamustine Non-Hodgkin lymphoma B-cell malignancy Relapsed disease Clinical trial

Erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment of stage IIIA-N2 EGFR-mutant non-small-cell lung cancer:final overall survival analysis of the EMERGING-CTONG 1103 randomised phase II trial

在线全文

学校读者我要写书评

暂无评论

Signal Transduction and Targeted Therapy 2023年第3期8卷 1310-1317页

作者： Wen-Zhao Zhong hong-hong yan Ke-Neng Chen chun Chen chun-Dong Gu Jun Wang Xue-Ning yang wei-Min Mao Qun Wang Gui-Bin Qiao Ying Cheng Lin Xu Chang-Li Wang ming-wei Chen xiao-Zheng Kang Wan-Pu yan Ri-Qiang Liao jin-Ji yang Xu-Chao zhang Si-yang Liu Qing zhou Yi-Long wu Guangdong Provincial People’s Hospital Guangdong Academy of Medical Sciences510080 GuangzhouChina Peking University Cancer Hospital and Institute 100142 BeijingChina Fujian Medical University Union Hospital 350001 FuzhouChina First Affiliated Hospital of Dalian Medical University 116011 DalianChina Peking University People’s Hospital 100044 BeijingChina Zhejiang Cancer Hospital 310022 HangzhouChina Zhongshan Hospital 200032 ShanghaiChina Guangzhou Liuhuaqiao Hospital 510000 GuangzhouChina Jilin Provincial Tumor Hospital 130012 ChangchunChina Jiangsu Cancer Institute and Hospital 210009 NanjingChina Tianjin Medical University Cancer Institute and Hospital 300060 TianjinChina First Affiliated Hospital of Xi’an Jiaotong University 710061 Xi’anChina

EMERGING-CTONG 1103 showed improved progression-free survival(PFS)with neoadjuvant erlotinib *** for patients harbouring EGFR sensibility mutations and R0 resected stage IIIA-N2 non-small cell lung cancer(NSCLC)(NCT01407822).Herein,we report the final *** patients were randomly allocated 1:1 to the erlotinib group(150 mg/day orally;neoadjuvant phase for 42 days and adjuvant phase to 12 months)or to the GC group(gemcitabine 1250 mg/m2 plus cisplatin 75 mg/m2 intravenously;2 cycles in neoadjuvant phase and 2 cycles in adjuvant phase).Objective response rate(ORR),complete pathologic response(pCR),PFS,and overall survival(OS)were assessed along with *** hoc analysis was performed for subsequent treatments after disease *** investigated 72 patients(erlotinib,n=37;GC,n=35),the median follow-up was 62.5 *** median OS was 42.2 months(erlotinib)and 36.9 months(GC)(hazard ratio[HR],0.83;95%confidence interval[CI],0.47-1.47;p=0.513).The 3-and_(5-y)ear OS rates were 58.6%and 40.8%with erlotinib and 55.9%and 27.6%with GC(p_(3-y)=0.819,p_(5-y)=0.252).Subsequent treatment was administered in 71.9%and 81.8%of patients receiving erlotinib and GC,respectively;targeted therapy contributed mostly to OS(HR,0.35;95%CI,0.18-0.70).After disease progression,the ORR was 53.3%,and the median PFS was 10.9 months during the EGFR-TKI *** postoperative therapy,grade 3 or 4 adverse events(AEs)were 13.5%in the erlotinib group and 29.4%in the GC *** serious adverse events were *** exhibited clinical feasibility for resectable IIIA-N2 NSCLC over chemotherapy in the neoadjuvant setting.

关键词： neoadjuvant cisplatin chemotherapy

A multiple-tissue-specific magnetic resonance imaging model for diagnosing Parkinson’s disease: a brain radiomics study

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Neural Regeneration Research 2022年第12期17卷 2743-2749页

作者： xiao-Jun Guan Tao Guo Cheng zhou Ting Gao jing-jing wu Victor Han Steven Cao hong-Jiang wei Yu-Yao zhang Min Xuan Quan-Quan Gu pei-Yu Huang chun-Lei Liu Jia-Li Pu Bao-Rong zhang Feng Cui xiao-Jun Xu Min-ming zhang Department of Radiology the Second Affiliated HospitalZhejiang University School of MedicineHangzhouZhejiang ProvinceChina Department of Neurology the Second Affiliated HospitalZhejiang University School of MedicineHangzhouZhejiang ProvinceChina Department of Electrical Engineering and Computer Sciences University of CaliforniaBerkeleyCAUSA Institute for Medical Imaging Technology School of Biomedical EngineeringShanghai Jiao Tong UniversityShanghaiChina School of Information Science and Technology ShanghaiTech UniversityShanghaiChina Helen Wills Neuroscience Institute University of CaliforniaBerkeleyCAUSA Department of Radiology Hangzhou Hospital of Traditional Chinese MedicineHangzhouZhejiang ProvinceChina

Brain radiomics can reflect the characteristics of brain ***,the value of T1-weighted images,quantitative susceptibility mapping,and R2*mapping in the diagnosis of Parkinson’s disease(PD)was underestimated in previous *** this prospective study to establish a model for PD diagnosis based on brain imaging information,we collected high-resolution T1-weighted images,R2*mapping,and quantitative susceptibility imaging data from 171 patients with PD and 179 healthy controls recruited from August 2014 to August *** to the inclusion time,123 PD patients and 121 healthy controls were assigned to train the diagnostic model,while the remaining 106 subjects were assigned to the external validation *** extracted 1408 radiomics features,and then used data-driven feature selection to identify informative features that were significant for discriminating patients with PD from normal controls on the training *** informative features so identified were then used to construct a diagnostic model for *** constructed model contained 36 informative radiomics features,mainly representing abnormal subcortical iron distribution(especially in the substantia nigra),structural disorganization(e.g.,in the inferior temporal,paracentral,precuneus,insula,and precentral gyri),and texture misalignment in the subcortical nuclei(e.g.,caudate,globus pallidus,and thalamus).The predictive accuracy of the established model was 81.1±8.0%in the training *** the external validation dataset,the established model showed predictive accuracy of 78.5±2.1%.In the tests of identifying early and drug-naïve PD patients from healthy controls,the accuracies of the model constructed on the same 36 informative features were 80.3±7.1%and 79.1±6.5%,respectively,while the accuracies were 80.4±6.3%and 82.9±5.8%for diagnosing middle-to-late PD and those receiving drug management,*** accuracies for predicting tremor-dominant and non-tremor-dominant PD w

关键词： diagnosis imaging biomarker iron magnetic resonance imaging neuroimaging Parkinson’s disease quantitative susceptibility mapping R2*mapping radiomics T1-weighted imaging

Impact factors of Blastocystis hominis infection in persons living with human immunodeficiency virus:a large-scale,multi-center observational study from China

在线全文

学校读者我要写书评

暂无评论

Infectious Diseases of Poverty 2023年第5期12卷 95-96页

作者： Shun-Xian zhang Ji-chun Wang Zhong-wei Li jin-Xin Zheng Wen-Ting zhou Guo-Bing yang Ying-Fang Yu Xiu-Ping wu Shan Lv Qin Liu Mu-Xin Chen yan Lu Zhi-Hui Dou Da-wei zhang Wen-Wen Lv Lei Wang Zhen-Hui Lu ming yang pei-Yong Zheng Yue-Lai Chen Li-Guang Tian xiao-Nong zhou Longhua Hospital Shanghai University of Traditional Chinese Medicine Shanghai China Chinese Center for Disease Control and Prevention (Chinese Center for Tropical Diseases Research) NHC Key Laboratory of Parasite and Vector Biology WHO Collaborating Centre for Tropical Diseases National Center for International Research On Tropical Diseases National Institute of Parasitic Diseases Shanghai China School of Global Health Chinese Center for Tropical Diseases Research-Shanghai Jiao Tong University School of Medicine Shanghai China Department of Science and Technology Chinese Center for Disease Control and Prevention Beijing China Gansu Province People’s Hospital Gansu Provincial Hospital Lanzhou China National Health Commission (NHC) Key Laboratory of Biosafety National Institute for Viral Disease Control and Prevention Chinese Center for Disease Control and Prevention Beijing China Gansu Provincial Center for Disease Control and Prevention Lanzhou China National Center for AIDS/STD Control and Prevention China Center for Disease Control and Prevention Beijing China The People’s Liberation Army 302 Hospital Beijing China Clinical Research Institute Shanghai Jiao Tong University School of Medicine Shanghai China

Background Blastocystis hominis(Bh)is zoonotic parasitic pathogen with a high prevalent globally,causing opportunistic infections and diarrhea *** immunodeficiency virus(HIV)infection disrupts the immune system by depleting CD4^(+)T lymphocyte(CD4^(+)T)cell counts,thereby increasing Bh infection risk among persons living with HIV(PLWH).However,the precise association between Bh infection risk and HIV-related biological markers and treatment processes remains poorly ***,the purpose of the study was to explore the association between Bh infection risk and CD4^(+)T cell counts,HIV viral load(VL),and duration of interruption in antiviral therapy among *** A large-scale multi-center cross-sectional study was conducted in China from June 2020 to December *** genetic presence of Bh in fecal samples was detected by real-time fluorescence quantitative polymerase chain reaction,the CD4^(+)T cell counts in venous blood was measured using flowcytometry,and the HIV VL in serum was quantified using fluorescence-based *** cubic spline(RCS)was applied to assess the non-linear association between Bh infection risk and CD4^(+)T cell counts,HIV VL,and duration of interruption in highly active antiretroviral therapy(HARRT).Results A total of 1245 PLWH were enrolled in the study,the average age of PLWH was 43 years[interquartile range(IQR):33,52],with 452(36.3%)being female,50.4%(n=628)had no immunosuppression(CD4^(+)T cell counts>500 cells/μl),and 78.1%(n=972)achieved full virological suppression(HIV VL<50 copies/ml).Approximately 10.5%(n=131)of PLWH had *** prevalence of Bh was found to be 4.9%[95%confidence interval(CI):3.8-6.4%]among *** nonlinear associations were observed between the Bh infection risk and CD4^(+)T cell counts(Pfor nonlinearity<0.001,L-shaped),HIV VL(Pfor nonlinearity<0.001,inverted U-shaped),and duration of interruption in HARRT(Pfor nonlinearity<0.001,inverted U-shaped).Conclusions

关键词： Blastocystis hominis Human immunodeficiency virus Viral load Non-linear association Restricted cubic spline Propensity score China

Interleukin-37 promotes colitis-associated carcinogenesis via SIGIRR-mediated cytotoxic T cells dysfunction

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Signal Transduction and Targeted Therapy 2022年第2期7卷 502-518页

作者： Zhen Wang Fan-lian Zeng Ya-wen Hu xiao-yan Wang Fu-lei Zhao pei zhou jing Hu Yuan-yuan xiao Zhong-lan Hu ming-feng Guo xiao-qiong wei xiao Liu Nong-yu Huang Jun zhang Shu-wen Chen Juan Cheng Hua-ping Zheng hong zhou Qi-xiang Zhao Chen zhang yan Hao Song Zou Yi-yue Gui Jia-dong Yu Lin-na Gu Cheng-cheng Yue Hao-zhou zhang Wen-ling wu Yi-fan zhou Xi-kun zhou Guo-bo Shen Xiu Teng Jiong Li State Key Laboratory of Biotherapy and Cancer Center West China HospitalWest China Medical SchoolSichuan University and Collaborative Innovation Center for BiotherapyChengduSichuan 610041China Department of Liver Surgery&Liver Transplantation West China HospitalSichuan University and Collaborative Innovation Center of BiotherapyChengduSichuan 610041China Laboratory of Liver Surgery West China HospitalSichuan UniversityChengduSichuan 610041China Department of Obstetrics and Gynecology West China Second University HospitalSichuan UniversityChengdu 610041China Key Laboratory of Birth Defects and Related Diseases of Women and Children Ministry of EducationSichuan UniversityChengdu 610041China Department of Cardiovascular Medicine West China HospitalSichuan UniversityChengduSichuan 610041China Laboratory of Human Disease and Immunotherapies West China HospitalSichuan UniversityChengduSichuan 610041China

Interleukin-37b(hereafter called IL-37)was identified as fundamental inhibitor of natural and acquired *** molecular mechanism and function of IL-37 in colorectal cancer(CRC)has been ***,we found that IL-37 transgenic(IL-37tg)mice were highly susceptible to colitis-associated colorectal cancer(CAC)and suffered from dramatically increased tumor burdens in ***,IL-37 is dispensable for intestinal mutagenesis,and CRC cell proliferation,apoptosis,and ***,IL-37 dampened protective cytotoxic T cell-mediated immunity in CAC and B16-OVA ***8^(+)T cell dysfunction is defined by reduced retention and activation as well as failure to proliferate and produce cytotoxic cytokines in IL-37tg mice,enabling tumor evasion of immune *** dysfunction led by IL-37 antagonizes IL-18–induced proliferation and effector function of CD8+T cells,which was dependent on SIGIRR(single immunoglobulin interleukin-1 receptor-related protein).Finally,we observed that IL-37 levels were significantly increased in CRC patients,and positively correlated with serum CRC biomarker CEA levels,but negatively correlated with the CD8+T cell infiltration in CRC *** findings highlight the role of IL-37 in harnessing antitumor immunity by inactivation of cytotoxic T cells and establish a new defined inhibitory factor IL-37/SIGIRR in cancerimmunity cycle as therapeutic targets in CRC.

关键词： immunity cytotoxic Interleukin

Association of Overlapped and Un-overlapped Comorbidities with COVID-19 Severity and Treatment Outcomes: A Retrospective Cohort Study from Nine Provinces in China

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Biomedical and Environmental Sciences 2020年第12期33卷 893-905页

作者： MA yan ZHU Dong Shan CHEN Ren Bo SHI Nan Nan LIU Si hong FAN Yi Pin wu Gui Hui yanG Pu Ye BAI Jiang Feng CHEN hong CHEN Li Ying FENG Qiao GUO Tuan Mao HOU Yong HU Gui Fen HU xiao Mei HU Yun hong HUANG jin HUANG Qiu Hua HUANG Shao Zhen JI Liang jin Hai Hao LEI xiao LI chun yan LI Min Qing LI Qun Tang LI Xian Yong LIU hong De LIU jin Ping LIU zhang MA Yu Ting MAO Ya MO Liu Fen NA Hui WANG jing wei SONG Fang Li SUN Sheng WANG Dong Ting WANG ming Xuan WANG xiao yan WANG Yin Zhen WANG Yu Dong wu wei wu Lan Ping xiao yan Hua XIE Hai Jun XU hong ming XU Shou Fang XUE Rui Xia yanG chun yanG Kai Jun YUAN Sheng Li zhang Gong Qi zhang jin Bo zhang Lin Song ZHAO Shu Sen ZHAO Wan Ying ZHENG Kai zhou Ying chun ZHU Jun Teng ZHU Tian Qing zhang Hua Min WANG yan Ping WANG Yong yan 无 Institute of Basic Research in Clinical Medicine China Academy of Chinese Medical SciencesBeijing 100700China Centre for Health Management and Policy Research School of Public HealthCheeloo College of MedicineShandong UniversityJinan 250012ShandongChina Institute of Information on Traditional Chinese Medicine China Academy of Chinese Medical SciencesBeijing 100700China Department of Tuberculosis The Public Health Clinical Center of ChengduChengdu 610066SichuanChina Department of Infectious Disease Shaanxi Infectious Disease HospitalXi'an 610113ShaanxiChina Department of Infectious Disease Yulin Chinese Medicine HospitalYulin 719000ShaanxiChina President's Office The First Hospital of QiqiharQiqihar 161005HeilongjiangChina Department of Traditional Chinese Medicine Shangluo Central HospitalShangluo 726000ShaanxiChina Department of Traditional Chinese Medicine The People's Hospital of QitaiheQitaihe 154603HeilongjiangChina Department of Scientific Research Xianyang Central HospitalXianyang 712000ShaanxiChina Department of traditional Chinese medicine The First Affiliated Hospital of Anhui University of Traditional Chinese MedicineHefei 230012AnhuiChina Department of Infectious Disease Heping Hospital Affiliated to Changzhi Medical CollegeChangzhi 046000ShanxiChina Department of Traditional Chinese Medicine Langfang Hospital of Chinese MedicineLangfang 065000HeibeiChina Department of Traditional Chinese Medicine Xingtai Hospital of Chinese MedicineXingtai 054001HeibeiChina Department of Traditional Chinese Medicine The People's Hospital of Guangxi Zhuang Autonomous RegionNanning 168600GuangxiChina Department of Traditional Chinese Medicine The First People'sHospital of FangchenggangFangchenggang 538001GuangxiChina Department of Traditional Chinese Medicine Mianyang Hospital of Traditional Chinese MedicineMianyang 621000SichuanChina Department of Traditional Chinese Medicine Liuzhou People's HospitalLiuzhou 545006GansuChina Department of Traditional Chinese Medici

Objective Several COVID-19 patients have overlapping comorbidities. The independent role of each component contributing to the risk of COVID-19 is unknown, and how some non-cardiometabolic comorbidities affect the risk of COVID-19 remains *** A retrospective follow-up design was adopted. A total of 1,160 laboratory-confirmed patients were enrolled from nine provinces in China. Data on comorbidities were obtained from the patients’ medical records. Multivariable logistic regression models were used to estimate the odds ratio(OR) and 95% confidence interval(95% CI) of the associations between comorbidities(cardiometabolic or non-cardiometabolic diseases), clinical severity, and treatment outcomes of *** Overall, 158(13.6%) patients were diagnosed with severe illness and 32(2.7%) had unfavorable outcomes. Hypertension(2.87, 1.30–6.32), type 2 diabetes(T2 DM)(3.57, 2.32–5.49),cardiovascular disease(CVD)(3.78, 1.81–7.89), fatty liver disease(7.53, 1.96–28.96), hyperlipidemia(2.15, 1.26–3.67), other lung diseases(6.00, 3.01–11.96), and electrolyte imbalance(10.40, 3.00–26.10)were independently linked to increased odds of being severely ill. T2 DM(6.07, 2.89–12.75), CVD(8.47,6.03–11.89), and electrolyte imbalance(19.44, 11.47–32.96) were also strong predictors of unfavorable outcomes. Women with comorbidities were more likely to have severe disease on admission(5.46,3.25–9.19), while men with comorbidities were more likely to have unfavorable treatment outcomes(6.58, 1.46–29.64) within two *** Besides hypertension, diabetes, and CVD, fatty liver disease, hyperlipidemia, other lung diseases, and electrolyte imbalance were independent risk factors for COVID-19 severity and poor treatment outcome. Women with comorbidities were more likely to have severe disease, while men with comorbidities were more likely to have unfavorable treatment outcomes.

关键词： Comorbidities COVID-19 Severity Gender Age Treatment outcome